ONCS Stock News 0.7950 05/06/2014 05:49:23 Oncosec Medical Inc

New Post Public Reply Private Reply Replies (0) Message Board

May 6, 2014 at 6:49 AM

Oncosec Medical Inc (ONCS) 0.7950 $ONCS

OncoSec Medical Presents New Data at 10th Annual PEGS: The Essential Protein Engineering Summit in Boston
Business Wire - Mon May 05, 5:15AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, today presented preliminary experimental findings demonstrating that electroporation with DNA-based IL-12 in mice can lead to systemic anti-tumor immune responses in distant untreated lesions. These data are consistent with the previously reported findings in melanoma patients treated in the Phase 2 OMSI100 study (December 2013).

OncoSec Medical to Present at Seven Events in May
Business Wire - Mon Apr 28, 5:03AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, will present at seven events in May. The company's itinerary includes a number of prominent scientific and investment conferences, culminating in a presentation at the 2014 ASCO Annual Meeting.

Super Stock Profits Top Five Small Cap Focus List: Onco Sec Medical, Inc. CannaVest Corp, AvWorks Aviation, MedBox, Inc. mCig, Inc.
PR Newswire Europe - Wed Apr 23, 6:05AM CDT
LONDON, April 23, 2014 /PRNewswire/ --

OncoSec Medical Names Adil Daud, M.D. as Chief Clinical Strategist
Business Wire - Wed Apr 23, 5:03AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, has named Adil Daud, M.D. as Chief Clinical Strategist.

OncoSec Medical Appoints New Executive Director of Research and Development
ACCESSWIRE - Tue Apr 22, 10:09AM CDT
OncoSec Medical Inc.'s (OTCQB: ONCS) share volume was strong Apr. 21 with 2,910,820 shares changing hands.

OncoSec Medical hires Dr Jean S. Campbell as executive director of its Research and Development
M2 - Tue Apr 22, 6:29AM CDT
Biopharmaceutical company OncoSec Medical (OTCQB:ONCS) revealed on Monday that it has named Jean S. Campbell, PhD to the newly created position of executive director of its Research and Development.

OncoSec Medical Selected to Present Phase II Data in Poster Highlights Session at 2014 ASCO Annual Meeting
Business Wire - Tue Apr 22, 5:02AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, will present an update of data from their Phase 2 melanoma study at the American Society of Clinical Oncology's 50th Annual Meeting, taking place May 30-June 3, 2014, at McCormick Place in Chicago, Illinois. Additional details will be made available on or after May 14, 2014, via the ASCO webpage: http://www.asco.org

OncoSec Medical Appoints Jean S. Campbell, Ph.D. as Executive Director of Research and Development
Business Wire - Mon Apr 21, 5:02AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, has appointed Jean S. Campbell, Ph.D. as Executive Director of Research and Development, a newly created position. Dr. Campbell, an Associate Professor in the Department of Pathology in the School of Medicine at the University of Washington, Seattle, will leverage her considerable expertise in cancer biology and signal transduction to investigate mechanisms of immune tolerance in cancer.

Elite Pharmaceuticals to Receive up to 40 Million from Lincoln Park Capital Fund
ACCESSWIRE - Tue Apr 15, 9:01AM CDT
Elite Pharmaceuticals Inc. (OTCBB: ELTP) announced Apr. 14 that it has entered into a common stock purchase agreement with Lincoln Park Capital Fund LLC ("LPC"

, a Chicago-based institutional investor for up to $40 million.

Aspen Insurance Turns down $3.2B Bid from Endurance Specialty Holdings; Herbalife Says Not Aware of Any Probe
ACCESSWIRE - Mon Apr 14, 11:38PM CDT
Aspen Insurance Holdings Ltd. (NYSE: AHL) - For an in-depth report on Aspen Insurance Holdings Ltd.: www.BullTrends.com/stockquote/AHL

OncoSec Medical to relaunch Phase II Cutaneous T-Cell lymphoma study at key centres of excellence in partnership with Stanford University
M2 - Mon Apr 07, 5:42AM CDT
Biopharmaceutical company OncoSec Medical (OTCQB:ONCS) said on Monday that it will restart its Phase II cutaneous T-cell lymphoma (CTCL) trial under a protocol amendment.

OncoSec Medical To Relaunch Phase II Cutaneous T-Cell Lymphoma Study at Key Centers of Excellence
Business Wire - Mon Apr 07, 5:03AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, will re-launch its Phase II cutaneous T-cell lymphoma (CTCL) trial under a protocol amendment.

OncoSec Medical to Present at Two Conferences in New York City in April
Business Wire - Mon Mar 31, 5:03AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, will present at the 13th Annual Needham Healthcare Conference and the HemOnc Today Melanoma and Cutaneous Malignancies Meeting in April.

PUNIT DHILLON of OncoSec Medical Incorporated (ONCS)-Other O bought Shares of ONCS
M2 - Fri Mar 21, 7:39AM CDT
Reported by InsiderCow.com at 2014-03-20 14:21:26 ET

OncoSec Medical to Present at 2nd Annual Sachs Cancer Bio Partnering & Investment Forum
Business Wire - Mon Mar 17, 5:03AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced that Punit Dhillon, President and CEO, will present a corporate overview of the company at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum at the New York Academy of Sciences on Wednesday, March 19th at 3:00 p.m. (EST).

OncoSec Medical to Evaluate Increased Dose Frequency of ImmunoPulse in Ongoing Phase II Melanoma Trial
Business Wire - Wed Mar 12, 5:02AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, announced today that the company has submitted a protocol addendum to the FDA and institutional IRBs to evaluate an increased dose frequency for ImmunoPulse in an expansion of its ongoing Phase II melanoma trial. The Company expects to enroll up to 21 patients in this expansion, and expects two additional key cancer centers as sites participating in this study.

OncoSec Medical to Present at 24th Annual Wall Street Analyst Forum Institutional Investor Conference
Business Wire - Tue Feb 25, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced that Punit Dhillon, President and CEO, will present a corporate overview of the company at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference at the University Club in New York, New York on Monday, March 3rd at 12:05 p.m. (EST).

OTC Daily Alert Stock Watch - OncoSec Medical Incorporated (OTCQB: ONCS)
WorldStockWire - Thu Feb 06, 2:45PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

OncoSec Medical to Present at 16th Annual BIO CEO & Investor Conference
Business Wire - Tue Feb 04, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced that Punit Dhillon, President and CEO, will present a corporate overview of the company at the 16th Annual BIO CEO & Investor Conference at the Waldorf Astoria in New York, New York on Monday, February 10 at 4:00 p.m. (EST) in the third floor Basildon Suite.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vylor's $3 Billion Buyback: A Long-Term Bet

Pumping Confidence with a Massive Buyback Vylor's big move to throw $3 billion into a share buyback isn't about short-term antics. This company's doubling down on long-term value creation, making sure every stakeholder knows they're in for the long haul. It's a gutsy move but what this step really tells us is, they've got faith in the business and a balance sheet that can...

Voter Power Flexes with Early Voting Celebrations

Voter Engagement Hits a New High with Nationwide Parties Well, look at that—voter turnout's got its own party scene now, and it's making waves. As Vote Early Day approaches, the folks at When We All Vote are cranking up the volume on civic engagement with what's touted as the biggest Party at the Polls program yet. With almost 700 get-togethers riffing across the U.S.,...

MLS Org's Sue Compass to Safeguard Fair Listing Access

Real Estate Clash: MLS vs. Compass Imagine flipping on the TV to see a legal showdown brewing in the real estate world — you've got six heavy-hitter MLSs facing off against Compass, Inc. Yeah, we're talking a legal slugfest here, folks, as these MLSs rally to keep the playing field level for over 120,000 agents across the country. They're not messing around, bringing a...

Sony's IMX742: Revolutionizing Endoscopic Imaging

Sony's Bold Move into Medical Tech You wouldn't expect a company like Sony to make waves in the medical field, but there they go again, shaking things up with their latest announcement. Lurking past the shiny consumer electronics, they've got the IMX742, a sensor designed for single-use endoscopes. A humble 1 mm square powerhouse, boasting about 0.51 megapixels of digital...

TruGolf's E6 Golf Platform Hits 15,000 Courses Milestone

E6's Expanding Universe of Courses TruGolf's E6 is swinging big with a library that's breaking records—more than 15,000 real-world golf courses now available on demand. It's a leap of 50% in under a year, an impressive stride for any tech-driven platform, golfing or otherwise. The magic behind this growth? On-demand generation, allowing the software's library to expand...

LCMC Health, Helix Collaborate for Genomics Future

What’s the Big Deal with Genomics? It's not every day you hear about a healthcare initiative aimed at making significant strides in genomics, and right in Louisiana’s backyard no less. LCMC Health has teamed up with Helix in a project that plans to involve 100,000 individuals. That’s a big number in research circles, indicating serious intent to redraw some...

Lyric Health's Grace: Transforming Virtual Healthcare

Grace in the Spotlight: A Game-Changer in Virtual Healthcare If you're tired of healthcare tech making big promises and delivering little, this might pique your interest. Lyric Health has rolled out Grace, a multimodal AI addition to their Virtual Care Operating System. This isn’t your run-of-the-mill chatbot — it’s a blend of proactive health monitoring,...

Local Visibility Crisis Looms for Small Businesses

Scrolling through these fresh stats from BrightLocal's recent report, you can almost hear the alarm bells echoing across small towns and city squares. The data paints a surprisingly sobering picture: despite the fact that 71% of folks are heading straight to Google to find local businesses, only a mere 22% of small business owners are tagging it as one of their top tools...

US Myeloma Network Revolutionizes Cancer Trials in U.S.

New Era for Myeloma Research In a move set to shake up the oncology world, the International Myeloma Foundation (IMF) is lighting a fire under clinical research with its ambitious US Myeloma Network (USMN). The whole shebang is about supercharging clinical trials and bringing real hope to folks battling multiple myeloma. If you've been watching the space, you know we're...

Wood Coatings Market Set for Sustainable Surge by 2032

Riding the Wave of Sustainable Coatings Who'd have thought we'd be chatting about wood coatings making such a splash? Turns out, this unsung hero of the materials world is gearing up for some serious growth, with the market projected to hit a crisp $33.34 billion by 2032. That's a decent jump from where it stands today, and it's all thanks to the shift towards...